Материнская гемодинамика и преэклампсия

1. Verburg P.E., Roberts C.T., McBean E., Mulder M.E., Leemaqz S., Erwich J.J.H.M., Dekker G.A. Peripheral maternal haemodynamics across pregnancy in hypertensive disorders of pregnancy, Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health (2019); S2210-7789(18)30148-X
2. Hausvater A., Giannone T., Sandoval Y.H.G., Doonan R.J., Antonopoulos C.N., Matsoukis I.L., Petridou E.T., Daskalopoulou S.S. The association between preeclampsia and arterial stiffness. J. Hypertens. 2012; 30:17–33. doi: 10.1097/HJH.0b013e32834e4b0f.
3. Khalil A., Cowans N.J., Spencer K., Goichman S., Meiri H., Harrington K. First-trimester markers for the prediction of preeclampsia in women with a-priori high risk, Ultrasound Obstet. Gynecol. 2010; 35: 671–9. doi: 10.1002/uog.7559.
4. Thilaganathan B. Pre-eclampsia and the cardiovascular–placental axis. Ultrasound Obstet Gynecol. 2018; 51: 714–7. Steegers E, Dadelszen P, Duvekot J, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376: 631-644. doi: 10.1016/S0140-6736(10)60279-6.
5. Steegers E, Dadelszen P, Duvekot J, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376: 631-644. doi: 10.1016/S0140-6736(10)60279-6.
6. Buurma A.J., Turner R.J., Driessen J.H.M., Mooyaart A.L., Schoones J.W., Bruijn J.A., Bloemenkamp K.W., Dekkers O.M., Baelde H.J. Genetic variants in pre-eclampsia: a meta-analysis. Hum Reprod Update.. 2013; 19(3): 289–303. doi: 10.1093/humupd/dms060
7. Johnson M.P., Brennecke S.P., East C.E., et al; FINNPEC Study Group. Genetic dissection of the pre-eclampsia susceptibility locus on chromo- some 2q22 reveals shared novel risk factors for cardiovascular disease. Mol Hum Reprod. 2013;19: 423–37. doi: 10.1093/molehr/gat011.
8. Staff A.C., Redman C.W.G., Williams D., Leeson P., Moe K., Thilaganathan B., Roberts J.M. Pregnancy and Long-Term Maternal Cardiovascular Health. Hypertension. 2016; 67(2): 251–60. doi: 10.1161/HYPERTENSIONAHA.115.06357.
9. Mounier-Vehier C., Madika A.-L., Boudghène-Stambouli F., Ledieu G., Delsart P., Tsatsaris V. Hypertensions artérielles de la grossesse et devenir maternel. La Presse Médicale. 2016; 45(7–8): 659–66. doi: 10.1016/j.lpm.2016.05.017
10. Sanghavi M., Rutherford J.D. Cardiovascular Physiology of Pregnancy. Circulation. 2014; 130(12):1003–8. doi: 10.1161/CIRCULATIONAHA.114.009029.
11. Mahendru A.A., Everett T.R., Wilkinson I.B., Lees C.C., McEniery C.M. A lon- gitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens. 2014; 32: 849–56. doi: 10.1097/HJH.0000000000000090.
12. Grindheim G., Estensen M.E., Langesaeter E., Rosseland L.A., Toska K. Changes in blood pressure during healthy pregnancy: a longitudinal cohort study. J Hypertens. 2012; 30: 342–350.
13. Jia R.Z., Liu X.M., Wang X., Wu H.Q. Relationship between cardiovascular function and fetal growth restriction in women with preeclampsia. Int J Gynaecol Obstet. 2010; 110: 61–3. doi: 10.1016/j.ijgo.2010.02.007
14. Valensise H., Vasapollo B., Gagliardi G., Novelli G.P. Early and late preeclamp- sia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008; 52: 873–80. doi: 10.1161/HYPERTENSIONAHA.108.117358
15. Stott D., Nzelu O., Nicolaides K.H., Kametas N.A. Maternal haemodynamics in normal pregnancies and in pregnancies affected by pre-eclampsia: Maternal haemodynamics in pre-eclampsia with FGR.  Ultrasound Obstet Gynecol. 2017; 52(3): 302–3. doi: 10.1002/uog.18835
16. Melchiorre K., Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol. 2011; 23(6): 440-7. doi: 10.1097/GCO.0b013e32834cb7a4.
17. Foo F.L., McEniery C.M., Lees, C., Khalil A. Assessment of arterial function in pregnancy: recommendations of the International Working Group on Maternal Hemodynamics. Ultrasound Obstet Gynecol. 2017; 50(3): 324–31. doi: 10.1002/uog.17565.
18. Van Bortel L.M., Laurent S., Boutouyrie P., Chowienczyk P., Cruickshank J.K., De Backer T., Filipovsky J., Huybrechts S., Mattace-Raso F.U., Protogerou A.D., Schillaci G., Segers P., Vermeersch S., Weber T., Artery S. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012; 30: 445–8 https://doi.org/10.1097/HJH.0b013e32834fa8b0
19. Hausvater A., Giannone T., Sandoval Y.H., Doonan R.J., Antonopoulos C.N., Matsoukis I.L., Petridou E.T., Daskalopoulou S.S. The association between preeclampsia and arterial stiffness. J Hypertens. 2012; 30:17–33. doi: 10.1097/HJH.0b013e32834e4b0f.
20. Khalil A., Garcia-Mandujano R., Maiz N., Elkhouli M., Nicolaides K.H. Longitudinal changes in maternal hemodynamics in a population at risk for pre-eclampsia. Ultrasound Obstet Gynecol. 2014; 44: 197–204. doi: 10.1002/uog.13367
21. Savvidou M.D., Kaihura C., Anderson J.M., Nicolaides K.H. Maternal arterial stiffness in women who subsequently develop pre-eclampsia. PLoS One. 2011; 6(5): e18703. doi: 10.1371/journal.pone.0018703
22. Khalil A., Akolekar R., Syngelaki A., Elkhouli M., Nicolaides K.H. Maternal hemodynamics at 11-13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol. 2012; 40: 28–34. doi: 10.1002/uog.11183
23. Osman M.W., Nath M., Breslin E., Khalil A., Webb D.R., Robinson, T.G., Mousa H.A. Association between arterial stiffness and wave reflection with subsequent development of placental-mediated diseases during pregnancy. Journal of Hypertension. 2018: 36(5); 1005–14. doi: 10.1097/HJH.0000000000001664
24. Melchiorre A.-K., Sharma R., Thilaganathan B. Cardiovascular implica- tions in preeclampsia: an overview. Circulation. 2014; 130: 703–714. doi: 10.1161/CIRCULATIONAHA.113.003664.
25. Wikström A.-K., Svensson T., Kieler H., et al. Recurrence of placental dysfunction disorders across generations. Am J Obstet Gynecol. 2011; 205: 454.e1-8. doi: 10.1016/j.ajog.2011.05.009.
26. Thilaganathan B. Association of Higher Maternal Blood Pressure With Lower Infant Birthweight: Placental Cause or Cardiovascular Effect? Hypertension. 2016; 67(3): 499–500. doi:10.1161/HYPERTENSIONAHA.115.06880
27. Pathak S., Lees C.C., Hackett G., Jessop F., Sebire N.J. Frequency and clinical sig- nificance of placental histological lesions in an unselected population at or near term. Virchows Arch. 2011; 459: 565–72. doi:10.1007/s00428-011-1157-z
28. Heida K.Y., Franx A., van Rijn B.B., Eijkemans M.J., Boer J.M., Verschuren M.W., Oudijk M.A., Bots M.L., van der Schouw Y.T. Earlier age of onset of chronic hypertension and type 2 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension. 2015; 66:1116–22. doi: 10.1161/HYPERTENSIONAHA.115.06005
29. Romundstad P.R., Magnussen E.B., Smith G.D., Vatten L.J. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122(6): 579–84. doi: 10.1161/CIRCULATIONAHA.110.943407
30. Roeters van Lennep J.E., Heida K.Y., Bots M.L. Hoek A; collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016; 23(2): 178–86. doi: 10.1177/2047487314556004.
31. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril 2016; 106(7): 1588–99. doi: 10.1016/j.fertnstert.2016.09.046.
32. Kalafat E., Laoreti A., Khalil A., Da Silva Costa, F., Thilaganathan B. Ophthalmic artery Doppler for prediction of pre-eclampsia: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2018; 51(6):731–7. doi:10.1002/uog.19002
33. Smith R.D., Levy P., Ferrario C.M. Consideration of Noninvasive Hemodynamic Monitoring to Target Reduction of Blood Pressure Levels Study Group. Value of noninvasive hemodynamics to achieve blood pres- sure control in hypertensive subjects. Hypertension. 2006; 47: 771–7. DOI: 10.1161/01.HYP.0000209642.11448.e0
34. Taler S.J., Textor S.C. Augustine J.E. Resistant hypertension: compar- ing hemodynamic management to specialist care. Hypertension. 2002; 39: 982–8. doi: 10.1161/01.hyp.0000016176.16042.2f
35. Valensise H., Vasapollo B., Gagliardi G., Novelli G.P. Early and late pre- eclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008; 52: 873–80. doi: 10.1161/HYPERTENSIONAHA.108.117358
36. Henderson J.T., Whitlock E.P., O’Connor E., Senger C.A., Thompson J.H., Rowland M.G. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160(10): 695–703. doi: 10.7326/M13-2844.
37. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A.; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007; 369(9575):1791–8. doi: 10.1016/S0140-6736(07)60712-0.
38. Rolnik D.L., Wright D., Poon L.C., et al. Aspirin versus placebo in pregnan- cies at high risk for preterm preeclampsia. N Engl J Med. 2017; 377(7): 613– 22. doi: 10.1056/NEJMoa1704559.
39. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122(5):1122–31. doi: 10.1097/01.AOG.0000437382.03963.88.
40. Duley L., Meher S., Jones L. Drugs for treatment of very high blood pres- sure during pregnancy. Cochrane Database Syst Rev. 2013; (3): CD001449. DOI: 10.1002/14651858.CD001449.pub2
41. Webster L.M., Myers J.E., Nelson-Piercy C., Harding K. Cruickshank J.K., Watt-Coote I., Khalil A., Wiesender C., Seed P.T., Chappell L.C. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial. Hypertension. 2017; 70: 915– 922. doi:10.1016/j.preghy.2019.05.004
42. Abalos E., Duley L., Steyn D.W. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014; (1): CD002252. doi: 10.1002/14651858.CD002252.pub2
43. Stott D., Papastefanou I., Paraschiv D., Clark K., Kametas N.A. Serial hemodynamic monitoring to guide treatment of maternal hypertension leads to reduction in severe hypertension. Ultrasound Obstet Gynecol. 2017; 49(1): 95–103. doi: 10.1002/uog.17341.
44. McLaughlin, K., Scholten, R.R., Kingdom, J.C., Floras, J.S., Parker, J.D. Should Maternal Hemodynamics Guide Antihypertensive Therapy in Preeclampsia? Hypertension. 2018; 71(4): 550–6. doi:10.1161/HYPERTENSIONAHA.117.10606
45. Goulopoulou S., Davidge S.T. Molecular mechanisms of maternal vascular dysfunc- tion in preeclampsia. Trends Mol Med. 2015; 21(2): 88–97. oi: 10.1016/j.molmed.2014.11.009.
46. Noble M.I., Drake-Holland A.J., Vink H. Hypothesis: arterial glycocalyx dysfunction is the first step in the atherothrombotic process. QJM. 2008; 101(7): 513–8. doi: 10.1093/qjmed/hcn024
47. Weissgerber T.L., Garcia Valencia O., Milic N.M., Codsi E., Cubro H.,Nath M.C., Garovic V.D. Early Onset Preeclampsia Is Associated With Glycocalyx Degradation and Reduced Microvascular Perfusion. J Am Heart Assoc. 2019; 8(4): e010647. doi: 10.1161/JAHA.118.010647.

Поступила 19.06.2019

Принята в печать 21.06.2019